Oppenheimer Starts Coverage on Spruce Biosciences with Bullish Outlook

Oppenheimer initiates coverage of Spruce Biosciences with an Outperform rating, citing strong FDA signals, accelerated approval potential, and possible acquisition interest from BioMarin.